Skip to content

ACCELERON PHARMA INC

Delisted

CIK 1280600fmd_02F8HBW31SR54NP9Q3KTFDN0D2Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2011 to Sep 30, 2021, 40 periods

Latest annual · FY2020

Millions
Total revenues
93
Operating income
(167)
Net income
(166)
Free cash flow
(135)

Latest quarter · Q3 FY2021

Millions
Total revenues
34
Operating income
(71)
Net income
(70)
Free cash flow
(73)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2017 to FY2020
+90.0%
Revenue, 5 yearsFY2015 to FY2020
+38.6%
Net income, 5 yearsFY2015 to FY2020
n/m

ACCELERON PHARMA INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2020FY2019ChangeSource
Revenue$92.5 million$74 million+25%10-K 2021-02-25 · proof
Operating income-$167.3 million-$136.4 million10-K 2021-02-25 · proof
Net income-$166 million-$124.9 million10-K 2021-02-25 · proof
Cash from operating activities-$130.3 million-$93.8 million10-K 2021-02-25 · proof
Free cash flow-$134.5 million-$97.1 million10-K 2021-02-25 · proof
Total assets$932.3 million$504.9 million+84.7%10-K 2021-02-25 · proof
Total liabilities$77.2 million$55.4 million+39.3%10-K 2021-02-25 · proof
Cash and cash equivalents$671 million$237.7 million+182.3%10-K 2021-02-25 · proof
What was ACCELERON PHARMA INC's revenue in fiscal 2020?
ACCELERON PHARMA INC reported revenue of $92.5 million for fiscal 2020 (the year ended Dec 31, 2020), against $74 million the year before (+25%). Source: the 10-K filed with the SEC on Feb 25, 2021. SEC
What was ACCELERON PHARMA INC's operating income in fiscal 2020?
ACCELERON PHARMA INC reported operating income of -$167.3 million for fiscal 2020 (the year ended Dec 31, 2020), against -$136.4 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2021. SEC
What was ACCELERON PHARMA INC's net income in fiscal 2020?
ACCELERON PHARMA INC reported net income of -$166 million for fiscal 2020 (the year ended Dec 31, 2020), against -$124.9 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2021. SEC
What was ACCELERON PHARMA INC's cash from operating activities in fiscal 2020?
ACCELERON PHARMA INC reported cash from operating activities of -$130.3 million for fiscal 2020 (the year ended Dec 31, 2020), against -$93.8 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2021. SEC
What was ACCELERON PHARMA INC's free cash flow in fiscal 2020?
ACCELERON PHARMA INC reported free cash flow of -$134.5 million for fiscal 2020 (the year ended Dec 31, 2020), against -$97.1 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2021. SEC
What are ACCELERON PHARMA INC's total assets?
As of Dec 31, 2020, ACCELERON PHARMA INC reported total assets of $932.3 million, against $504.9 million a year earlier (+84.7%). Source: the 10-K filed with the SEC on Feb 25, 2021. SEC
What are ACCELERON PHARMA INC's total liabilities?
As of Dec 31, 2020, ACCELERON PHARMA INC reported total liabilities of $77.2 million, against $55.4 million a year earlier (+39.3%). Source: the 10-K filed with the SEC on Feb 25, 2021. SEC
What are ACCELERON PHARMA INC's cash and cash equivalents?
As of Dec 31, 2020, ACCELERON PHARMA INC reported cash and cash equivalents of $671 million, against $237.7 million a year earlier (+182.3%). Source: the 10-K filed with the SEC on Feb 25, 2021. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1280600&period_type=annual&limit=5"

Information only, not investment advice.